Urinary Tract Infection And Extended-Spectrum Beta-Lactamase Escherichia Coli

Main Article Content

Atieh Makhlough, Mohammad Ahanjan, Marjan Makhlough, Ali Mirabi, Marjan Onogh, Lotfollah Davoodi


Antimicrobial-resistant strains of gram negative bacteria are one of the fundamental obstacles in the treatment of Escherichia Coli (E. coli) producing the extended-spectrum beta-lactamase (ESBLs). Resistance to antimicrobial beta-lactam drugs that used to treat bacterial infections has created a major concern. The aim of this study was to determine the prevalence of ESBL producing strains of E. coli in urinary tract infection in Sari city hospitals and also to determine their susceptibility to them to the different antibiotics. This cross-sectional study was done during 2013-2014. Urine samples were cultured on blood agar and McConkey agar. The subtraction tests were immediately performed if the growth of bacteria was observed in culture media. Antibiotics resistance was assessed using following antibiotics: cefotaxime, ceftazidime, imipenem, nalidixic acid, cefixime, amikacin, ofloxacin, ceftriaxone, cefepime, gentamicin, tobramycin, meropenem, piracetam, and ciprofloxacin. From November 2013 to June 2014, 200 urine samples were collected; 120 (60%) of whom were E. coli positive that 66 (55%) of which were ESBL producers. ESBL producing strains of E. coli showed the highest susceptibility to meropenem (66%) and ofloxacin (63%); and showed the highest rates of resistance to ceftazidime (60%), cefepime (57%), cefotaxime and ceftriaxone (56%).Considering the high prevalence of resistance to third-generation cephalosporins in infections caused by organisms producing ESBL, performing comprehensive tests before prescribing antibiotics is absolutely essential.

Article Details